Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC Phase 3 trial of teprotumumab in active thyroid eye disease
2017-002763-18Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) and Graves' ophthalmopathy (TED) comparing Teprotumumab with Placebo (2 arms). Primary endpoint: Proptosis responder rate at Week 24. Started Nov 2017; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2017-002763-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002763-18.